A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
- 1 February 2022
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 55, 86-95
Abstract
No abstract availableKeywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Next-generation genotype imputation service and methodsNature Genetics, 2016
- Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic reviewPsychiatry Research, 2016
- Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorderTranslational Psychiatry, 2015
- A Fast Method that Uses Polygenic Scores to Estimate the Variance Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a TraitThe American Journal of Human Genetics, 2015
- Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depressionJournal of Psychopharmacology, 2013
- Outlier and influence diagnostics for meta-analysisResearch Synthesis Methods, 2010
- The Interleukin 1 Beta (IL1B) Gene Is Associated with Failure to Achieve Remission and Impaired Emotion Processing in Major DepressionBiological Psychiatry, 2010
- Conducting Meta-Analyses inRwith themetaforPackageJournal of Statistical Software, 2010
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003